The MFHR1 fusion protein is a novel synthetic multitarget complement inhibitor with therapeutic potential
Michelfelder S, Fischer F, Wäldin A, Hörle KV, Pohl M, Parsons J, Reski R, Decker EL, Zipfel PF, Skerka C, Häffner K.
J Am Soc Nephrol. 2018;29(4):1141-1153
J Am Soc Nephrol. online article
The complement system is essential for the host defense but its uncontrolled activation leads to pathologic signaling, resulting in renal diseases like aHUS and C3 glomerulopathy. The novel synthetic fusion protein MFHR1 modulates complement activation by targeting C3 as well as terminal pathway. MFHR1 blocks hemolysis mediated by a patient’s serum and ameliorates C3 glomerulopathy in vivo in FH-/- mice. The strong inhibitory activity of MFHR1 offers a novel basis for complement therapeutics.
